| Abbas Elmahdi, Ahmed | Using Machine Learning to Predict RNA Pol II Interactions of Metastatic Prostate Cancer |
| Acharya, Bipul | Human iPSC-derived prostate organoids with germline BRCA2 mutation undergo tumorigenic transformations |
| Aftab, Blake | ADI-212: A next-generation gene-edited and armored allogeneic CAR γδ T cell therapy targeting PSMA for prostate cancer |
| Agarwal, Neeraj | Real-world treatment patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitor (ARPI) or docetaxel
ProstACT Global: A phase 3 study of Lutetium (Lu177) rosopatamab tetraxetan plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer |
| Akamatsu, Shusuke | Transdifferentiation of prostate adenocarcinoma to carcinosarcoma |
| Al Hussein Al Awamlh, Bashir | Health Literacy in Prostate Cancer |
| Askary, Amjad | Resolving Cellular and Metabolic Heterogeneity of Liver mCRPC with Single-Cell Spatial Transcriptomics |
| Au, Cheuk Man Cherie | Molecular Glue Degraders of AR/AR-V7: A Paradigm Shift in the Treatment of Advanced Prostate Cancer |
| Bakht, Martin | The SHAPE Cohort: Integrated Genomic and Spatial Profiling of Advanced Prostate Cancer With and Without Lu-PSMA Treatment |
| Bellows, Eleanor | Epitranscriptomic reprogramming and enzalutamide resistance in prostate cancer |
| Blinka, Steven | SPEN mutations as a biomarker for androgen receptor signaling inhibitor therapy resistance in metastatic prostate cancer |
| Brault, Lise | Development of tools to define single-cell evolution of prostate cancer metastasis under therapeutic pressure |
| Brown, LaKendria | Vitamin D Increases Sensitivity to Radiotherapy in Advanced Metastatic African American Prostate Cancer Cell Lines |
| Burnham, Leanne | Spatially Resolved HER2 and AR in Prostate Cancer Highlight HER2 as a Distinct Therapeutic Target |
| Buteau, James | Combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer: first analysis of the single-center phase I/II AlphaBet trial |
| Cackowski, Frank | Single Cell Analysis Reveals Upregulation of Immune Stimulatory Pathways in Quiescent Metastatic Castration Resistant Prostate Cancer Cells |
| Casanova-Salas, Irene | Integrated ctDNA and EV-RNA analysis uncovers tumor evolution and lineage plasticity in metastatic Prostate Cancer |
| Chan, Chung Ying | Preclinical evaluation of 68Ga/177Lu-KK02, a theranostic targeting PARP for PARP-expressing cancers |
| Chaudagar, Kiranj | Therapeutic vulnerability of prostate cancer to VPAC antagonism |
| Chu, Carissa | FACS-based Whole-genome CRISPRi Screen to Uncover STEAP1 Regulators in Prostate Cancer |
| Cole, Alexander | ROADMAP: Hospital and Physician Characteristics Associated with Imaging, Genetic Testing and Molecular Diagnostics |
| Cooper, Aaron | Preclinical development of AB-3028, a programmable circuit CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC) |
| Cooperberg, Matthew | The practice of active surveillance for prostate cancer: trends, variation, and quality within a large national health system |
| Darst, Burcu | HSD3B1 (1245A>C) germline variant and prostate cancer progression in low- and favorable intermediate-risk patients |
| de la Calle, Claire | Use of the Prostate Health Index in Predicting Adverse Oncologic Outcomes on Active Surveillance |
| Dee, Edward Christopher | National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis of Global Data |
| Dias, Mikhail | Mapping the targetable proteome of metastatic castration-resistant prostate cancer |
| Diaz, Johnny | New approach to model genetically defined hormone-naïve castration-sensitive human prostate cancer |
| Ding, Chien-Kuang | Artificial Intelligence-based Detection of Neuroendocrine Carcinoma of Prostate in Metastatic Biopsies |
| Dornisch, Anna | Specificity of a Polygenic Score for Aggressive Prostate Cancer |
| Drake, Justin | A liquid biopsy-based targeted proteomic assay to identify actionable targets for late-stage prostate cancer |
| Einstein, David | National Cancer Institute’s Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations |
| Elkenawi, Asmaa | Mapping Mitochondrial interaction in prostate Cancer |
| Eltit Guersetti, Felipe | Proteomics Analysis to Characterize Prostate Cancer Bone Metastases Subtypes |
| Fallatah, Arwa | Discern the Impact of Cryptochrome 1 (CRY1) on Metabolic Rewiring in PCa |
| Flanagan, Sinead | A Low Insulinemic Diet and Lifestyle for the Primary Prevention of Aggressive Prostate Cancer with PTEN Loss. |
| Fletcher, Claire | A MicroRNA Approach to Directly Induce Potent DNA Damage in Transcriptionally-Hyperactive Prostate Cancer Cells, and Delivery via Biocompatible ‘Nanogels’ |
| Fonseca, Nicolette | Circulating tumour DNA (ctDNA) based detection of genetic immune escape in advanced prostate cancer (aPCa) |
| Freeman, Michael | ONECUT2 reprograms the AR network and activates non-canonical EZH2 in aggressive prostate cancer |
| Freeman, Michael | ONECUT2 as a Central Regulator of Neuroendocrine Fate and Immune Silencing in Small Cell Lung Cancer |
| George, Daniel | Disparities in Prostate-Specific Membrane Antigen (PSMA)-Targeted Imaging Utilization Among Patients With Advanced Prostate Cancer (PC) |
| Godolphin, Peter | Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC): STOPCAP meta-analysis of individual participant data (IPD) |
| Gong, Jun | A nationwide VA study on first-line systemic treatment patterns in Black men with metastatic castration-resistant prostate cancer |
| Grist, Emily | Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers |
| Grunberg, Nil | Communication between prostate tumours and peri-prostatic adipose drives obesity-associated prostate cancer aggressivity |
| Gueron, Geraldine | Targeting Glycolysis and Mitochondrial Function in Prostate Cancer with Carbon Monoxide Releasing Molecules |
| Guilbault, Denise | Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BIPASS) |
| Haas, Roni | Joint Biochemical & Genetic Prostate Cancer Risk Stratification |
| Hayes, Vanessa | HEROIC Prostate Cancer Precision Health Africa1K: updates from the Genomics & Data Science Working Group |
| Hossain, Md Niamat | The αVβ3 integrin/NgR2 complex is upregulated in NEPrCa and is a novel therapeutic target |
| Hsiung, Chris | Engineered CRISPR-Cas12a for combinatorial functional genomics in prostate cancer |
| Hsu, Sarah | Dissecting tumor cell state heterogeneity in advanced prostate cancer |
| Jamaspishvili, Tamara | Artificial Intelligence (AI)-Driven Quantification of p53 Expression Improves Prognostic Stratification in Prostate Cancer |
| Jamieson, Christina | Therapeutic development of ULK1/2 inhibitors as adjuvant therapy in bone metastatic prostate cancer |
| Jarrard, David | Histone-Modifying Enzymes in Androgen-Deprived Prostate Cancer: EZH1 as a Synergistic Therapeutic Target |
| Kensler, Kevin | Trends in GLP-1 receptor agonist use among men with prostate cancer |
| Kalac, Matko | Final overall survival (OS) with talazoparib plus enzalutamide as first-line treatment in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the Phase 3 TALAPRO-2 trial |
| Kang, Dong-Woo | Effects of Exercise on Cardiometabolic and Immunological Biomarkers in Men with Prostate Cancer on Active Surveillance: Findings from the ERASE Randomized Controlled Trial |
| Kimmel, Blaise | Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates |
| Kosoff, David | Screening of primary cancer-associated fibroblast drug sensitivity to guide rational design of cancer-associated fibroblast-targeted antibody-drug conjugates in prostate cancer |
| Kotula, Leszek | ABI1 as liquid biopsy biomarker of ARPI resistance |
| Kregel, Steven | SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer |
| Ku, Anson | Club-like cells and PIGR expression are associated with inflammatory high-risk, localized prostate cancer |
| Kumar, Rajendra | Targeting GPX4 to enhance ferroptosis in supraphysiologic androgen-treated prostate cancer. |
| Kwon, Daniel | Evaluating an Artificial Intelligence (AI) Communication Platform for Racial Biases in Information Quality about Prostate Cancer (PCa) Germline Testing |
| Labanca, Estefania | Targeting Ketone Body Metabolism in Advanced Treatment-Resistant Prostate Cancer |
| Labbé, David | Precision nutrition to potentiate radiotherapy |
| Laird, Douglas | Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2 |
| Lallous, Nada | Androgen Receptor Variant 7 (AR-V7) Condensates Promote Growth and Proliferation in Castration-Resistant Prostate Cancer |
| Leiter, Amanda | Diabetes Increases Cardiovascular Mortality but Not Prostate Cancer Mortality Among Men Receiving Androgen Deprivation Therapy |
| Li, Chennan | A novel metastatic prostate cancer model from an African American man with small-cell characteristics |
| Li, Haolong | Targeting the PTGES3-AR axis in Advanced Prostate Cancer |
| Lin, Neil | Modeling of Drug Synergies in AR-Resistant Prostate Cancer Using a Digital Twin |
| Link, Charles | Clinical Activity and Safety of SYNC-T Therapy SV-102 in Patients with Metastatic Prostate Cancer |
| Loeb, Stacy | Barriers and Facilitators to Lifestyle Modification in Prostate Cancer |
| Lyu, Aram | Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastases |
| Macarro, Carlos | Deep Learning for Prostate Cancer BRCA Mutation Detection and Phenotypic Characterization from Histopathology |
| Madan, Ravi | Prospective Monitoring of Prostate Specific Membrane Antigen (PSMA) in Biochemically Recurrent Prostate Cancer (BCR): Preliminary Data from 1 Year Follow-up |
| Mahajan, Kiran | Targeting HOXB13 Mediated Immune Suppression of Castration-Resistant Prostate Cancers |
| Mahajan, Nupam | Phase 1 First in man Trial of Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer |
| Maher, Christopher | Methylation signature to distinguish indolent and aggressive prostate cancer |
| Mao, Zhiyuan | Tuning TCR Immunotherapy Targeting Prostatic Acid Phosphatase via Catchbond Modifications for Advanced Prostate Cancer |
| Mehraj, Umar | Targeting NUAK2 disrupts pre-mRNA splicing and inhibits neuroendocrine prostate cancer |
| Mir, Nabiel | Tolerability and the Accelerome: Wrist-Worn Open-Source Accelerometry Tracks Symptom Burden in Androgen-Ablated Older Men with Metastatic Prostate Cancer |
| Moran, Amy | The androgen receptor tunes CD8+ T cell effector and memory responses to acute infection |
| Morrissey, Colm | The Continued Relevance of the Seed and Soil Hypothesis to Metastatic tumor Dissemination, Distribution, and Therapy Resistance with an Emphasis on Liver Metastasis in Castration-Resistant Prostate Cancer |
| Murad, John | Optimization of Safe and Effective PSCA-CAR/IL12 Engineered T cell Combinatorial Treatment Strategies Against Metastatic Prostate Cancer |
| Nelson, Colleen | Novel therapeutic development for aggressive variant prostate cancer |
| Newman, Lauren | Unlocking the potential of large oncosomes as a liquid biopsy tool for prostate cancer through next generation capture and detection methods |
| Pacheco, Nicollette | 64Cu-SAR-bisPSMA PET/CT and SOC PSMA PET/CT in Biochemical Recurrence of Prostate Cancer: A Close-Up of the Phase II COBRA Trial |
| Pachynski, Russell | Chemerin augments antitumor immunity in prostate cancer via enhanced antigen presentation and NK/CD8⁺ T cell recruitment |
| Pandey, Apurva | Conditionally activated membrane binding probes for improved targeted radiotherapy |
| Papachristodoulou, Alex | Establishment of pre-clinical models for the discovery of new mitochondrial biomarkers of high-risk prostate cancer |
| Patel, Dhiren | ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrates potent anti-tumor activity and overcomes resistance to enzalutamide and 177Lu-PSMA-617 in prostate cancer models |
| Patel, Hiten | Not in Plain Sight: Identifying Pathological Features of MRI Invisible Prostate Cancer |
| Patel, Krishnan | Transcriptomic-Clinical Risk Stratification to Guide Abiraterone Treatment Intensification in High-Risk Prostate Cancer: A Combined Analysis of NRG/RTOG 9202, 9413, 9902, and 0521 |
| Patnaik, Akash | Spatially organized lymphocytic microenvironments in high-grade primary prostate cancer |
| Patnaik, Akash | Androgen receptor blockade primes NLRP3 in tumor-associated macrophages to enhance NLRP3 agonist-mediated phagocytosis and tumor control |
| Pattabiraman, Diwakar | Discovery of Helicon Peptides for the Selective Degradation of the Agonist-Bound Conformation of Androgen Receptor (ARon) in Prostate Cancer |
| Patton, Robert | A deep learning framework for predicting gene expression from cell-free DNA |
| Poluben, Larysa | Enhancing Androgen Receptor Antagonist-Mediated Interferon Responses in Prostate Cancer |
| Punnen, Sanoj | Evaluation of AI-based and Genomic Prognostic Markers for the Prediction of Grade Progression in the Prostate Cancer Active Surveillance Setting |
| Quigley, David | Single-Cell Multi-Omics Reveals the Molecular Landscape and Heterogeneity of Metastatic Castration-Resistant Prostate Cancer |
| Rajendran, Rithika | HER2-Targeted Therapy in Metastatic Castration-Resistant Prostate Cancer: Phase II Trial in Progress and Case Report of Abiraterone Re-challenge with Trastuzumab Deruxtecan |
| Rajendran, Rithika | Characterization of HER2 Expression in Prostate Cancer Compared with Other Solid Tumors |
| Robert-Tissot, Celine | Real World Evidence Reveals Sustained Androgen Receptor (AR) Expression and Activity As Resistance Mechanism to AR Signaling Inhibitors in Metastatic Castration-Resistant Prostate Cancer |
| Rojo Domingo, Mariluz | Refining Risk Stratification in Grade Group 2 Prostate Cancer: The Role of Multiparametric MRI in Detecting Cribriform and Intraductal Carcinoma |
| Romero, Rodrigo | Elucidating Drivers of Neuroendocrine Plasticity in Mouse Models of Prostate Cancer |
| Rosen, Daniel | Detection and Targeting of Genomic Fusion Derived pMHC Neoantigens in Prostate Cancer |
| Sabbagh, Ali | Development and external validation of a computational approach for early read out of randomized clinical trials in metastatic prostate cancer |
| Sachdeva, Ashwin | Major Adverse Cardiovascular Events in high risk localised and metastatic hormone sensitive prostate cancer in four phase III STAMPEDE platform protocol trials |
| Sanchis, Pablo | Bone-derived signals activate PKA and promote resistance to AR-targeted therapies in prostate cancer. |
| Sanin, David | Myeloid Cell Regulation in Patients with Advanced Prostate Cancer treated with Bipolar Androgen Therapy |
| Scheinberg, Tahlia | Plasma lipidomics and PCPro as prognostic biomarkers in TheraP (ANZUP 1603): a randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) |
| Schmidt, Daniel | Targeting Pyruvate Kinase to Induce Metabolic Dependencies in Prostate Cancer |
| Schoen, Martin | A novel tumor genomic classification system accurately stratifies patients with metastatic prostate cancer into distinct prognostic groups |
| Scurll, Joshua | The genomic-transcriptomic landscape of high-risk localized prostate cancer in the Genomic Umbrella Neoadjuvant Study |
| Sena, Laura | IDH1 and IDH2 mutations in prostate cancer |
| Sharifi, Marina | Clinical impact of high-risk genomic mutations and prostate cancer lineage state identified through high purity circulating tumor cell RNA sequencing in patients with metastatic prostate cancer |
| Sharma, Komal | Machine Learning-based Detection of Concurrent DNA Repair Deficiencies as Dynamic Biomarkers for Prostate Cancer Precision Medicine |
| Shibata, Maho | Derepression of endogenous retroviral elements promotes extracellular matrix remodeling and immune cell evasion in prostate cancer |
| Shobaki, Nour | An All-in-One ‘Living Drug’ CAR T Cell Platform for Safe and Effective Targeting of Metastatic Castration-Resistant Prostate Cancer |
| Sim, Woogwang | Uncovering Compensatory Innate Immune Checkpoints to Target Aggressive Variant Prostate Cancer |
| Sirohi, Deepika | Correlation of Canary Histological Patterns at Radical Prostatectomy with Decipher GRID Basal and Luminal Signature Score. |
| Sirohi, Deepika | Validation of Canary Histological Patterns at Radical Prostatectomy with Decipher GRID Prognosis Signature Score |
| Sjöström, Martin | Non-invasive prostate cancer subtyping using 5hmC-sequencing of cell-free DNA |
| Soh, Pamela | Prostate cancer genetic risk in Africa: evaluating polygenic risk scores and germline testing |
| Sokolova, Alexandra | TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response |
| Stoyanova, Tanya | Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis |
| Subudhi, Sumit | The Path Forward for CD28-Targeted T Cell Engagers in Prostate Cancer |
| Sumiyoshi, Takayuki | Transcriptome analysis of de novo metastatic castration-sensitive prostate cancer using long-read sequencing technologies |
| Sutera, Philip | Evaluating associations between genomic classifier and digital pathology based multi-modal AI biomarkers in localized and metastatic prostate cancer |
| Takeda, David | Mechanism of AR enhancer activation in castration-resistant prostate cancer |
| Tendler, Salomon | Actinium-225 Radioimmunotherapy in Delta-like Ligand 3 NEPC tumor model |
| Tolmeijer, Sofie | Blood and imaging response correlatives in advanced prostate cancer treated with combination radioligand and immunotherapy |
| Trock, Bruce | Physical Activity and Risk of Prostate Cancer Grade Reclassification on Active Surveillance: Results from a Prospective Cohort Study |
| Tsao, Phoebe | Impact of androgen receptor pathway inhibitors on mental health in Veterans with metastatic hormone-sensitive prostate cancer |
| Venkadakrishnan, Varadha Balaji | Modulation Of Chromatin Bivalency Facilitates Prostate Cancer Lineage Plasticity |
| Wala, Jeremiah | Spatially organized lymphocytic microenvironments in high grade primary prostate tumors |
| Wang, Zhipeng | Roles, Regulations, and Therapeutic Potential of the Lysine Acetoacetylome in Prostate Cancer |
| Washington III, Samuel | Heterogeneity of community drivers of social vulnerability across racial groups of men with prostate cancer |
| Weiner, Adam | Molecular Characterization of Imaging-Invisible Prostate Tumors |
| Weller, Sarah | Improving prostate cancer outcomes globally: A Movember update |
| Wurzer, Alexander | A preclinical evaluation on the radiohybrid tandem [18F]La- and [225Ac]Ac-rhPSMA-10.1 for targeted alpha therapy of prostate cancer |
| Wyatt, Alex | CDK12 is a prostate cancer predisposition gene |
| Xu, George | Predicting Active Surveillance Failure in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study |
| Xu, Ping | Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy |
| Xu, Xin | RNA Epitranscriptomic editing Screening Identifies Functional m6A Sites in Prostate Cancer |
| Ye, Huihui | Mitochondrial Metabolic Reprogramming Orchestrates Tumor–Immune Crosstalk and Dictates Disease Outcomes in Primary Prostate Cancer |
| Younger, Noah | Identification and characterization of PLUTO-201, a novel lncRNA associated with prostate cancer metastasis |
| Zhao, Di | Histone Methyltransferase ASH1L Primes Metastases and Metabolic Reprogramming of Macrophages in the Bone Niche |
| Zhao, Faming | Deciphering single-cell heterogeneity and cellular ecosystem dynamics during prostate cancer progression |
| Zhu, Xiaolin | Targeting SSTR1 to overcome resistance to androgen receptor signaling inhibition in prostate cancer |
| Zorko, Nicholas | Determining Optimal NK Cell Features for Immune Engagement with Tri-specific Killer Engager Molecules |
